275 related articles for article (PubMed ID: 16601244)
1. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia.
Del Principe MI; Del Poeta G; Buccisano F; Maurillo L; Venditti A; Zucchetto A; Marini R; Niscola P; Consalvo MA; Mazzone C; Ottaviani L; Panetta P; Bruno A; Bomben R; Suppo G; Degan M; Gattei V; de Fabritiis P; Cantonetti M; Lo Coco F; Del Principe D; Amadori S
Blood; 2006 Aug; 108(3):853-61. PubMed ID: 16601244
[TBL] [Abstract][Full Text] [Related]
2. Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis.
Sheikholeslami MR; Jilani I; Keating M; Uyeji J; Chen K; Kantarjian H; O'Brien S; Giles F; Albitar M
Cytometry B Clin Cytom; 2006 Jul; 70(4):270-5. PubMed ID: 16906585
[TBL] [Abstract][Full Text] [Related]
3. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
Schroers R; Griesinger F; Trümper L; Haase D; Kulle B; Klein-Hitpass L; Sellmann L; Dührsen U; Dürig J
Leukemia; 2005 May; 19(5):750-8. PubMed ID: 15759031
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia.
D'Arena G; Tarnani M; Rumi C; Vaisitti T; Aydin S; De Filippi R; Perrone F; Pinto A; Chiusolo P; Deaglio S; Malavasi F; Laurenti L
Am J Hematol; 2007 Sep; 82(9):787-91. PubMed ID: 17534928
[TBL] [Abstract][Full Text] [Related]
5. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM
Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313
[TBL] [Abstract][Full Text] [Related]
6. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
Rassenti LZ; Huynh L; Toy TL; Chen L; Keating MJ; Gribben JG; Neuberg DS; Flinn IW; Rai KR; Byrd JC; Kay NE; Greaves A; Weiss A; Kipps TJ
N Engl J Med; 2004 Aug; 351(9):893-901. PubMed ID: 15329427
[TBL] [Abstract][Full Text] [Related]
7. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.
Weinberg JB; Volkheimer AD; Chen Y; Beasley BE; Jiang N; Lanasa MC; Friedman D; Vaccaro G; Rehder CW; Decastro CM; Rizzieri DA; Diehl LF; Gockerman JP; Moore JO; Goodman BK; Levesque MC
Am J Hematol; 2007 Dec; 82(12):1063-70. PubMed ID: 17654680
[TBL] [Abstract][Full Text] [Related]
8. ZAP-70 staining in chronic lymphocytic leukemia.
Villamor N
Curr Protoc Cytom; 2005 May; Chapter 6():Unit 6.19. PubMed ID: 18770822
[TBL] [Abstract][Full Text] [Related]
9. Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method.
Gachard N; Salviat A; Boutet C; Arnoulet C; Durrieu F; Lenormand B; Leprêtre S; Olschwang S; Jardin F; Lafage-Pochitaloff M; Penther D; Sainty D; Reminieras L; Feuillard J; Béné MC;
Haematologica; 2008 Feb; 93(2):215-23. PubMed ID: 18223290
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia.
Molica S; Vitelli G; Cutrona G; Todoerti K; Mirabelli R; Digiesi G; Giannarelli D; Sperduti I; Molica M; Gentile M; Morabito F; Neri A; Ferrarini M
Int J Hematol; 2008 Nov; 88(4):374-380. PubMed ID: 18818986
[TBL] [Abstract][Full Text] [Related]
11. ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia.
Catherwood MA; Matthews C; Niblock R; Dobbin E; Morris TC; Alexander HD
Eur J Haematol; 2006 Apr; 76(4):294-8. PubMed ID: 16519700
[TBL] [Abstract][Full Text] [Related]
12. Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL.
Morilla A; Gonzalez de Castro D; Del Giudice I; Osuji N; Else M; Morilla R; Brito Babapulle V; Rudenko H; Matutes E; Dearden C; Catovsky D; Morgan GJ
Leuk Lymphoma; 2008 Nov; 49(11):2108-15. PubMed ID: 19021053
[TBL] [Abstract][Full Text] [Related]
13. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia.
Buhl AM; Jurlander J; Geisler CH; Pedersen LB; Andersen MK; Josefsson P; Petersen JH; Leffers H
Eur J Haematol; 2006 Jun; 76(6):455-64. PubMed ID: 16529606
[TBL] [Abstract][Full Text] [Related]
14. ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations.
Zucchetto A; Bomben R; Bo MD; Nanni P; Bulian P; Rossi FM; Del Principe MI; Santini S; Del Poeta G; Degan M; Gattei V
Cytometry B Clin Cytom; 2006 Jul; 70(4):284-92. PubMed ID: 16906587
[TBL] [Abstract][Full Text] [Related]
15. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients.
Meuleman N; Stamatopoulos B; Dejeneffe M; El Housni H; Lagneaux L; Bron D
Leukemia; 2008 Oct; 22(10):1882-90. PubMed ID: 18633433
[TBL] [Abstract][Full Text] [Related]
16. Zap-70 and CD38 as predictors of IgVH mutation in CLL.
Cruse JM; Lewis RE; Webb RN; Sanders CM; Suggs JL
Exp Mol Pathol; 2007 Dec; 83(3):459-61. PubMed ID: 17931624
[TBL] [Abstract][Full Text] [Related]
17. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach.
Passam F; Tachynopoulou V; Skoumi D; Tsompanakou A; Stavropoulos-Giokas A; Vadikolia C; Anagnostopoulos A; Paterakis G
Ann Hematol; 2006 Nov; 85(11):795-805. PubMed ID: 16871389
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia.
Del Principe MI; Del Poeta G; Venditti A; Buccisano F; Maurillo L; Marini R; Cox MC; Panetta P; Suppo G; Degan M; Bruno A; Gattei V; Amadori S
Haematologica; 2004 Dec; 89(12):1468-75. PubMed ID: 15590397
[TBL] [Abstract][Full Text] [Related]
20. Telomere length, molecular cytogenetic findings, and immunophenotypic features in previously untreated patients with B-chronic lymphocytic leukemia.
Brezinova J; Berkova A; Vcelikova S; Zemanova Z; Izakova S; Sarova I; Cechova H; Tajtlova J; Grosova L; Lizcova L; Malinova E; Zemanova M; Cmunt E; Karban J; Trneny M; Schwarz J; Michalova K
Neoplasma; 2010; 57(3):215-21. PubMed ID: 20353271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
